Search

Your search keyword '"Djurfeldt, Marina S"' showing total 19 results
Start Over Author "Djurfeldt, Marina S"
19 results on '"Djurfeldt, Marina S"'

3. Salvage chemotherapy and autologous stem cell transplantation for transformed indolent lymphoma: a subset analysis of NCIC CTG LY12

Author

Kuruvilla, John, MacDonald, David A., Kouroukis, C. Tom, Cheung, Matthew, Olney, Harold J., Turner, A. Robert, Anglin, Peter, Seftel, Matthew, Ismail, Walid Sabry, Luminari, Stefano, Couban, Stephen, Baetz, Tara, Meyer, Ralph M., Hay, Annette E., Shepherd, Lois, Djurfeldt, Marina S., Alamoudi, Sameer, Chen, Bingshu E., and Crump, Michael

Published
2015
Full Text
View/download PDF

6. The conditional survival analysis of relapsed DLBCL after autologous transplant: a subgroup analysis of LY.12 and CORAL.

Author

UCL - SSS/DDUV - Institut de Duve, UCL - SSS/DDUV/BCHM - Biochimie-Recherche métabolique, UCL - (SLuc) Service d'hématologie, Assouline, Sarit, Li, Shen, Gisselbrecht, Christian, Fogarty, Patrick, Hay, Annette, Van Den Neste, Eric, Shepherd, Lois E, Schmitz, Norbert, Baetz, Tara, Keating, Armand, Robinson, Sue, Seftel, Matthew, Stelitano, Caterina, Djurfeldt, Marina S, Meyer, Ralph, Chen, Bingshu E, Crump, Michael, UCL - SSS/DDUV - Institut de Duve, UCL - SSS/DDUV/BCHM - Biochimie-Recherche métabolique, UCL - (SLuc) Service d'hématologie, Assouline, Sarit, Li, Shen, Gisselbrecht, Christian, Fogarty, Patrick, Hay, Annette, Van Den Neste, Eric, Shepherd, Lois E, Schmitz, Norbert, Baetz, Tara, Keating, Armand, Robinson, Sue, Seftel, Matthew, Stelitano, Caterina, Djurfeldt, Marina S, Meyer, Ralph, Chen, Bingshu E, and Crump, Michael

Abstract

The conditional survival of patients after frontline therapy for diffuse large B-cell lymphoma (DLBCL) approaches that of the general population once patients have survived disease free for 2 years. We sought to determine the conditional survival of patients among patients with relapsed de novo DLBCL successfully undergoing an autologous stem-cell transplant (ASCT) after first relapse. A total of 478 patients with de novo DLBCL, relapsed after 1 treatment from the Collaborative Trial in Relapsed Aggressive Lymphoma (CORAL) and LY.12, were included. Patients were followed prospectively after ASCT for a median of 5.3 and 8.2 years, respectively. Individual patient data were analyzed for event-free survival (EFS) and overall survival. Standardized mortality ratios (SMRs) were estimated using French and Canadian life tables. The EFS estimates declined with each year of follow-up after ASCT and were 50.1% (95% confidence interval [CI]: 43.7% to 56.3%) and 43.4% (95% CI: 36.7% to 49.9%) at 5 years in CORAL and LY.12, respectively. The rate of death stabilized once patients achieved at least 4 years of EFS. Compared with the age- and sex-matched population, the SMR was significantly higher until 5 years after ASCT, when values were no longer statistically significant. Patients undergoing ASCT for relapsed DLBCL continue to have a higher rate of death at least until they have survived event free for 5 years. These observations can help to determine endpoints for future clinical trials in this population and for patient counseling. This trial was registered at www.clinicaltrials.gov as #NCT00078949.

Published
2020

8. Randomized Comparison of ABVD Chemotherapy With a Strategy That Includes Radiation Therapy in Patients With Limited-Stage Hodgkin’s Lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group

Author

Meyer, Ralph M., Gospodarowicz, Mary K., Connors, Joseph M., Pearcey, Robert G., Bezjak, Andrea, Wells, Woodrow A., Burns, Bruce F., Winter, Jane N., Horning, Sandra J., Dar, A Rashid, Djurfeldt, Marina S., Ding, Keyue, and Shepherd, Lois E.

Published
2005
Full Text
View/download PDF

9. Event-Free Survival As a Surrogate for Overall Survival in Relapsed DLBCL after Autologous Transplant: A Subgroup Analysis of LY.12 and Coral

Author

Assouline, Sarit, primary, Li, Shen, primary, Gisselbrecht, Christian, primary, Fogarty, Patrick, primary, Hay, Annette E., primary, Van Den Neste, Eric, primary, Shepherd, Lois E., primary, Schmitz, Norbert, primary, Baetz, Tara, primary, Keating, Armand, primary, Robinson, Sue, primary, Seftel, Matthew D., primary, Stelitano, Caterina, primary, Djurfeldt, Marina S., primary, Meyer, Ralph, primary, Chen, Bingshu E., primary, and Crump, Michael, primary

Published
2019
Full Text
View/download PDF

10. Impact of Wait Times for Autologous Stem Cell Transplantation in Patients with Aggressive Non-Hodgkin Lymphoma, a Subset Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Clinical Trial

Author

Skamene, Tanya, primary, Jiang, Wenyu, additional, Meyer, Ralph M., additional, Crump, Michael, additional, Kuruvilla, John, additional, Kouroukis, C. Tom, additional, Luminari, Stefano, additional, Couban, Stephen, additional, Cheung, Matthew C., additional, Rizzieri, David A, additional, Bardy, Peter G, additional, Pater, Joseph, additional, Djurfeldt, Marina S., additional, Shepherd, Lois E., additional, Chen, Bingshu E, additional, and Hay, Annette E, additional

Published
2016
Full Text
View/download PDF

11. Effect of the addition of rituximab to salvage chemotherapy prior to autologous stem cell transplant in aggressive CD20+ lymphoma: a cohort comparison from the NCIC Clinical Trials Group Study LY.12*

Author

Baetz, Tara, primary, Chen, Bingshu E., additional, Couban, Stephen, additional, Tom Kouroukis, C., additional, Buckstein, Rena, additional, Kuruvilla, John, additional, Howson-Jan, Kang, additional, Szwajcer, David, additional, Federico, Massimo, additional, Meyer, Ralph M., additional, Djurfeldt, Marina S., additional, Hay, Annette E., additional, Shepherd, Lois, additional, and Crump, Michael, additional

Published
2016
Full Text
View/download PDF

14. Potential Utility of Event-Free Survival (EFS) As Surrogate Endpoint for Overall Survival (OS) in Relapsed Diffuse Large B-Cell Lymphoma (DLBCL) after Autologous Stem Cell Transplantation (ASCT): A Subgroup Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Randomized Phase III Trial

Author

Li, Shen, Hay, Annette E, Crump, Michael, Anglin, Peter, Baetz, Tara, Meyer, Ralph, Keating, Armand, Robinson, Sue, Seftel, Matthew, Stelitano, Caterina, Djurfeldt, Marina S, Shepherd, Lois E., Chen, Bingshu E., and Assouline, Sarit

Published
2017
Full Text
View/download PDF

15. Effect of the addition of rituximab to salvage chemotherapy prior to autologous stem cell transplant in aggressive CD20+ lymphoma: a cohort comparison from the NCIC Clinical Trials Group Study LY.12.

Author

Baetz, Tara, Chen, Bingshu E., Couban, Stephen, Tom Kouroukis, C., Buckstein, Rena, Kuruvilla, John, Howson-Jan, Kang, Szwajcer, David, Federico, Massimo, Meyer, Ralph M., Djurfeldt, Marina S., Hay, Annette E., Shepherd, Lois, and Crump, Michael

Subjects
LYMPHOMA treatment, RITUXIMAB, STEM cell transplantation, AUTOTRANSPLANTATION, CANCER chemotherapy
Abstract

The impact of the addition of rituximab to salvage chemotherapy prior to autologous stem cell transplant (ASCT) was evaluated in a retrospective subgroup analysis of NCIC CTG LY.12. Among 414 patients who relapsed following R-CHOP, 96 received salvage chemotherapy alone [R − cohort]; and 318 received rituximab with chemotherapy [R + cohort] following a protocol amendment. The R−cohort had a higher proportion of patients with PS ≥2 and relapse <1 year after R-CHOP. The response rate (45.6% vs. 25.0%,p = 0.0003), CR/CRu (15.7% vs. 4.2%,p = 0.003) and transplantation rate (51.9% vs. 31.3%,p = 0.0004) was higher in the R + cohort. Event-free (27% vs. 22%,p = 0.0954) and overall survival at four years (43% vs. 31%;p = 0.045) were greater in the R + cohort when the patients with best response SD/PD to R-CHOP were excluded. Addition of rituximab to salvage therapy before ASCT appears to improve the response rate, transplantation rate, and overall survival in patients with CD20+ lymphoma who responded to R-CHOP. [ABSTRACT FROM PUBLISHER]

Published
2017
Full Text
View/download PDF

16. Addition of Rituximab to Salvage Chemotherapy in Aggressive CD20+ Lymphoma Prior to Autologous Stem Cell Transplant (ASCT): A Cohort Comparison from the NCIC CTG Study LY.12

Author

Baetz, Tara, primary, Chen, Bingshu E, additional, Couban, Stephen, additional, Kouroukis, C. Tom, additional, Buckstein, Rena, additional, Kuruvilla, John, additional, Howson-Jan, Kang, additional, Szwajcer, David, additional, Federico, Massimo, additional, Meyer, Ralph M., additional, Turner, Robert, additional, Djurfeldt, Marina S, additional, Hay, Annette E, additional, Shepherd, Lois, additional, and Crump, Michael, additional

Published
2014
Full Text
View/download PDF

17. Randomized Comparison of Gemcitabine, Dexamethasone, and Cisplatin Versus Dexamethasone, Cytarabine, and Cisplatin Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: NCIC-CTG LY.12

Author

Crump, Michael, primary, Kuruvilla, John, additional, Couban, Stephen, additional, MacDonald, David A., additional, Kukreti, Vishal, additional, Kouroukis, C. Tom, additional, Rubinger, Morel, additional, Buckstein, Rena, additional, Imrie, Kevin R., additional, Federico, Massimo, additional, Di Renzo, Nicola, additional, Howson-Jan, Kang, additional, Baetz, Tara, additional, Kaizer, Leonard, additional, Voralia, Michael, additional, Olney, Harold J., additional, Turner, A. Robert, additional, Sussman, Jonathan, additional, Hay, Annette E., additional, Djurfeldt, Marina S., additional, Meyer, Ralph M., additional, Chen, Bingshu E., additional, and Shepherd, Lois E., additional

Published
2014
Full Text
View/download PDF

18. Final Analysis of a Randomized Comparison of ABVD Chemotherapy with a Strategy That Includes Radiation Therapy (RT) in Patients with Limited-Stage Hodgkin Lymphoma (HL): NCIC CTG/ECOG HD.6

Author

Meyer, Ralph M., primary, Gospodarowicz, Mary, additional, Connors, Joseph M., additional, Pearcey, Robert G, additional, Wells, Woodrow A, additional, Winter, Jane N., additional, Horning, Sandra J., additional, Dar, A. Rashid, additional, Shustik, Chaim, additional, Stewart, Douglas A., additional, Crump, Michael, additional, Djurfeldt, Marina S, additional, Chen, Bingshu E, additional, and Shepherd, Lois E, additional

Published
2011
Full Text
View/download PDF

19. Relapse Patterns and Subsequent Outcomes of Patients Treated on the NCIC CTG HD.6 (ECOG JHD06) Randomized Trial Evaluating ABVD Alone in Patients with Limited Stage Hodgkin Lymphoma (HL).

Author

Macdonald, David A., primary, Gospodarowicz, Mary K., primary, Wells, Woodrow A., primary, Pearcey, Robert G., primary, Connors, Joseph M., primary, Winter, Jane N., primary, Horning, Sandra J., primary, Djurfeldt, Marina S., primary, Ding, Keyue, primary, Shepherd, Lois E., primary, and Meyer, Ralph M., primary

Published
2005
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results